看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。5 L9 q# d$ i5 h; k
, ~4 {& Y3 J, v, b. p
* [# u, _2 U: Z" ~% D
Currently available feasibility data for possible combination strategies. & r: l e& k1 o3 y8 O, W7 O0 I9 Q
————————————————————————————————6 M0 O4 D, F8 w) l5 R1 o* [8 p ]
Combination Feasibility according to preliminary data * [, G8 u* w3 s1 S' U# v
——————————————————————————————————
- t- q8 {8 x; ?) A8 G6 yBevacizumab + sorafenib Yes, reduced dose + U7 ?1 S0 B0 X) x o
Bevacizumab + sunitinib† No
, C2 e3 B$ x9 y& e7 M/ rBevacizumab + temsirolimus Yes
' Z8 k# r6 _6 d: @6 P4 XBevacizumab + everolimus Yes A2 l) V+ K% J2 t [, k
Sorafenib + sunitinib ? 8 K* j- O- U O z. R/ u* N4 z
Sorafenib + temsirolimus Yes, reduced dose 6 Z$ I; ~/ v/ p" C
Sorafenib + everolimus Yes, reduced dose
2 H# m6 b1 B( F' i9 hSunitinib + temsirolimus† No 4 K# f, y( W/ M* n6 t& H( {9 \; I
Sunitinib + everolimus ?
6 b" q. l) `. e9 t3 U7 Y2 ^Temsirolimus + everolimus ?
( {; n- a9 x- f4 T————————————————————
?. I9 ^0 e& P3 D* @' _0 M†Led to US FDA warning.# ]' D6 Z/ t! C/ J* F8 H
?: As yet unattempted combination.; \3 I$ w" i8 A
|